BlackRock Amends Sangamo Therapeutics Stake (SC 13G/A)
Ticker: SGMO · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1001233
| Field | Detail |
|---|---|
| Company | Sangamo Therapeutics, Inc (SGMO) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock just updated its Sangamo Therapeutics stake, watch for market reaction.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating a change in its ownership of Sangamo Therapeutics Inc. common stock as of December 31, 2023. This filing, Amendment No. 4, updates BlackRock's previous disclosures regarding its passive investment in the biotechnology company. This matters to investors because BlackRock is a major institutional investor, and changes in its holdings can signal shifts in confidence or investment strategy, potentially influencing other investors' perceptions of Sangamo Therapeutics' stock.
Why It Matters
This filing shows BlackRock, a major institutional investor, has updated its position in Sangamo Therapeutics, which can influence market sentiment and other investors' decisions.
Risk Assessment
Risk Level: low — This is a routine update from a passive institutional investor and does not inherently signal significant risk.
Analyst Insight
Investors should monitor subsequent filings from BlackRock or Sangamo Therapeutics for more specific details on BlackRock's updated stake, as this filing only indicates an amendment without disclosing the new percentage of ownership.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person filing the SC 13G/A
- Sangamo Therapeutics Inc. (company) — the subject company whose securities are being reported
- January 26, 2024 (date) — the filing date of the SC 13G/A
- December 31, 2023 (date) — the date of the event requiring the filing
- Amendment No. 4 (number) — the specific amendment number of the filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4)' sections.
Who is the subject company whose shares are being reported?
The subject company is SANGAMO THERAPEUTICS INC, as indicated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC'.
Who is the entity that filed this report?
The entity that filed this report is BlackRock Inc., as stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as specified under '(Date of Event Which Requires Filing of this Statement)'.
What is the CUSIP number for the securities reported?
The CUSIP number for the securities, which are Common Stock of Sangamo Therapeutics Inc., is 800677106, as listed under 'CUSIP No. 800677106'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding SANGAMO THERAPEUTICS, INC (SGMO).